The overall ratings of 11 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Mallinckrodt Plc (MNK) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of MNK stock.

Pacira Pharmaceuticals, Inc. (PCRX) declines this week from a D to a F. Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company with focuses on the development, commercialization, and manufacturing of proprietary pharmaceutical products. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PCRX stock.

Slipping from a C to a D rating, Collegium Pharmaceutical, Inc. (COLL) takes a hit this week. The company also gets F’s in earnings revisions, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of COLL stock.

This week, Endo International Plc (ENDP) drops from a D to a F rating. Endo International Plc provides specialty healthcare solutions in the United States and internationally. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ENDP stock.

This is a rough week for Intra-Cellular Therapies, Inc. (ITCI). The company’s rating falls to F from the previous week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ITCI stock.

Omeros Corporation (OMER) gets weaker ratings this week as last week’s C drops to a D. Omeros Corporation is a biopharmaceutical company developing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of OMER stock.

Intersect ENT Inc’s (XENT) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of XENT stock.

Egalet Corporation (EGLT) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EGLT stock.

Adamis Pharmaceuticals Corporation (ADMP) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ADMP stock.

This week, Cerecor Inc’s (CERC) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CERC stock.

DURECT Corporation (DRRX) slips from a D to a F this week. DURECT Corporation is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of DRRX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.